Supplementary Table S3 shows plasma levels of BAs in the total population, which are simultaneously stratified by T2DM status and use of incretins (i.e., DPP-4 inhibitors or GLP-1 receptor agonists). This evidence concerns the gene GCG and type 2 diabetes mellitus.